BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 25899862)

  • 1. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
    Kebriaei P; Poon ML
    Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.
    Advani AS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():131-7. PubMed ID: 24319174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
    Dias A; Kenderian SJ; Westin GF; Litzow MR
    Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of antibody therapy in ALL.
    Ai J; Advani A
    Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapies in Acute Lymphoblastic Leukemia.
    Phelan KW; Advani AS
    Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.
    Turtle CJ; Riddell SR; Maloney DG
    Clin Pharmacol Ther; 2016 Sep; 100(3):252-8. PubMed ID: 27170467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antibody therapy in acute lymphoblastic leukemia.
    Kochuparambil ST; Litzow MR
    Curr Hematol Malig Rep; 2014 Jun; 9(2):165-73. PubMed ID: 24623281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
    Liu D; Zhao J; Song Y; Luo X; Yang T
    J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.
    Viardot A; Sala E
    Expert Opin Investig Drugs; 2021 Jul; 30(7):773-784. PubMed ID: 33998346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agents in Development for Childhood Acute Lymphoblastic Leukemia.
    Maloney KW; Gore L
    Paediatr Drugs; 2018 Apr; 20(2):111-120. PubMed ID: 29143289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions in chimeric antigen receptor T cell therapy.
    Maude SL
    Curr Opin Pediatr; 2017 Feb; 29(1):27-33. PubMed ID: 27841776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in adult acute leukemia.
    Blum S; Martins F; Lübbert M
    Leuk Res; 2017 Sep; 60():63-73. PubMed ID: 28756350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.